| 1 | 205871-1 : n : 03/02/2020 : PMG* / tgw LSA2020-20346 |
|----|--|
| 2 | |
| 3 | ORR AMENDMENT NO. 2 TO SUBSTITUTE FOR SB165 |
| 4 | |
| 5 | |
| 6 | |
| 7 | |
| 8 | On page 8, delete lines 18 through 20 and insert in |
| 9 | lieu thereof the following: |
| 10 | (12) MEDICAL CANNABIS. a. A medical grade product |
| 11 | with a tetrahydrocannabinol potency of no greater than 10 |
| 12 | percent, certified in compliance with Good Manufacturing |
| 13 | Processes such that the product is shown to meet intended |
| 14 | levels of purity and reliably free of toxins and contaminants. |
| 15 | The product may be in the form of any of the following, as |
| 16 | determined by rule by the commission, with a |
| 17 | tetrahydrocannabinol concentration of no greater than 10 |
| 18 | percent, that contains a derivative of cannabis for medical |
| 19 | |
| 20 | On page 8, line 24, delete "Gelatinous" and insert |
| 21 | in lieu thereof the following: |
| 22 | Unflavored and non-sugar-coated gelatinous |